As Editor of ATLA for about 35 years, I have written many editorials and comments. Today, however, faced with the need for an editorial for this issue, I find myself so overwhelmed by concerns about the world in general and about the Three Rs in particular, that I am finding it difficult to write a single word.
Looking at the wider world, I see increasing atrocities resulting from prejudice and war, leading to terrorism, anti-semitism, enforced exile and unwelcome immigration. I have just been to Belgium, for a moving and deeply-meaningful visit to the battlefields of Waterloo, World War I and World War II. My concern is that the human race has learned nothing from those dreadful events, except how to develop better weapons which would kill more enemy troops and citizens.
On the Three Rs front, it increasingly seems that lessons are not being learned and leading to satisfactory progress. For example, in the UK we are faced with a Government policy to promote the use of e-cigarettes (ECs), which are claimed to be 95% safer that conventional smoking tobacco products (CSTPs). There is no evidence to support such a claim. Meanwhile, the number of tobacco smokers in the world continues to increase, and nobody wants to face up to the possible long-term adverse consequences of the vaping of contrived and perfumed, heated nicotine mixtures. The danger is that new animal testing facilities will be required, first to somehow quantitatively establish the harm resulting from CSTPs and the promise of modifiedrisk tobacco products, 1 then to show that vaping via ECs is "safer". During the first few weeks after its publication, there were more that 4,000 reads on ResearchGate of an article on the safety testing of ECs, of which I was a co-author 2 -40 reads would have been a very good number, so there may be grounds for hope there.
On another front, my colleagues, Michelle Thew and Jarrod Bailey, and I have shown that tests on laboratory animals cannot be used to establish that new drugs will be sufficiently safe for approval for use by humans. [3] [4] [5] More than 95% of new drugs have to be withdrawn during clinical trials or even after their acceptance for clinical use, because of unexpected lack of efficacy or unpredicted adverse side-effects, but governments, the pharmaceutical industry, and many pharmacologists and toxicologists remain wedded to reliance on animal testing. We have received or seen no criticism of our method of analysis itself, but its outcome is either being ignored altogether, or we are told that "We are fully committed to the Three Rs, but we believe that animal studies are essential". Where is the evidence that animal tests provide relevant and reliable knowledge to the benefit of patients?
During the last few days, a new challenge has emerged -a long overdue waking-up to the urgent need for new antibiotics, to overcome microbial resistance to the existing drugs, a problem which is said to result in 50,000 deaths each year in the USA and Europe alone -a number which is likely to increase, unless new drugs are found without delay. There are to be a number of joint government-industry initiatives, because it seems that the pharmaceutical industry is unwilling to invest in the necessary research on its own. Let us hope that this will lead to success, and that the resulting profits will be shared with taxpayers and not just handed out in drug company dividends. Meanwhile, I wonder how the new antibiotics will be discovered and developed, and the extent to which this will depend on giving animals infectious diseases, with and without the candidate compounds.
The fundamental problem is that promises of commitment to the Three Rs, and of openness and transparency, mean little or nothing in a world where risk assessment and health policies are all-too-often based on likelihood and plausibi-
